Test Price
1,500 AED✅ Home Collection Available
Chronic Lymphocytic Leukemia (CLL) Mutations Detection Comprehensive Panel – Dubai, UAE
Executive Summary & Core Metrics
- ✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing — MLPA + PCR multiplex analysis.
- ✓Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (8 AM – 11 PM daily).
- ✓Clinical Guidance: Telephonic Post-Test Clinical Guidance for result interpretation by qualified clinical counselors.
- ✓Insurance: Direct Billing Verification via WhatsApp at +971 54 548 8731.
- ✓DHA Licensed: Facility License No. 1143 | Dubai Healthcare City.
Core Metrics
Price: 1,500 AED (All-Inclusive)
Turnaround Time: 6 Days (Sample arrival Mon 11 AM → Report by Saturday)
Sample Type: Whole Blood (4 mL EDTA Lavender Top)
Methodology: MLPA + PCR Multiplex
Test Overview & Methodology
The Chronic Lymphocytic Leukemia (CLL) Mutations Detection Comprehensive Panel is a high-precision molecular diagnostic assay that identifies clinically actionable genetic mutations — including TP53, ATM, IGHV, NOTCH1, SF3B1, BIRC3, and MYD88 — guiding oncologists in risk stratification and targeted therapy selection. Our methodology uses Multiplex Ligation-dependent Probe Amplification (MLPA) combined with PCR to achieve a 99.9% diagnostic sensitivity, far exceeding standard FISH assays.
| Feature | Our CLL Comprehensive Panel | Closest Alternative (Standard FISH) |
|---|---|---|
| Methodology | MLPA + PCR (Multiplex Ligation-dependent Probe Amplification) | FISH (Fluorescence In Situ Hybridization) |
| Diagnostic Sensitivity | 99.9% | ~85–90% |
| Genetic Markers Detected | TP53, ATM, IGHV, NOTCH1, SF3B1, BIRC3, MYD88 + comprehensive panel | Limited (typically 4–6 markers) |
| Turnaround Time | 6 Days (Mon 11 AM → Sat Report) | 10–14 Days |
| Price (AED) | 1,500 (All-Inclusive) | Variable |
Physician Insight & Safety Protocols
"As a specialist in diagnostic radiology with extensive experience in CLL molecular diagnostics, I emphasize that this comprehensive mutation panel provides critical prognostic and therapeutic information. Genetic findings — particularly TP53 disruption and IGHV mutation status — must always be interpreted in the full clinical context alongside flow cytometry, cytogenetics, and clinical staging. Every result carries a unique implication for your treatment journey, and I urge all patients to review findings with their treating oncologist before making any therapeutic decisions."
— Mr. Prabhakar Reddy Kalathoor, DHA Registration ID: 61713011
Specialist Diagnostic Radiology | DNA Labs UAE
Advisory: Medication Safety
⚠ Important
Do not discontinue prescribed medication without consulting your doctor. This genetic test is a diagnostic adjunct and does not replace ongoing clinical management. Any modification to chemotherapy, targeted therapy, or supportive care regimens must be directed exclusively by your treating oncologist or hematologist.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria (Relative):
- Hemoglobin below 7 g/dL (discuss with ordering physician)
- Active severe systemic infection or sepsis
- Inability to provide informed consent (see Federal Decree-Law No. 4 of 2016 on Medical Liability — Minors)
- Recent blood transfusion within 48 hours (may affect circulating cell populations)
ER Red Flags — Seek Immediate Medical Attention:
- Sudden onset of severe fatigue or pallor
- Unexplained fever above 38.5°C persisting >24 hours
- Unexplained bruising, petechiae, or mucosal bleeding
- Rapidly enlarging lymph nodes or splenic discomfort
- Unintentional weight loss exceeding 10% in 6 months
This panel is a diagnostic tool, not an emergency service. For any acute symptoms, proceed to the nearest DHA-licensed emergency department immediately.
Patient FAQ & Clinical Guidance
1. What genetic mutations does the CLL Comprehensive Panel detect, and how do they impact my treatment plan?
The CLL Mutations Detection Comprehensive Panel identifies clinically actionable genetic alterations including TP53, ATM, IGHV, NOTCH1, SF3B1, and BIRC3 mutations that directly guide targeted therapy selection and risk stratification in chronic lymphocytic leukemia. TP53-disrupted patients, for instance, show markedly inferior responses to standard chemoimmunotherapy and are typically directed toward novel agents such as BTK inhibitors or BCL-2 antagonists. IGHV mutation status remains one of the most powerful independent prognostic factors, with unmutated IGHV conferring a more aggressive disease course requiring closer monitoring and earlier intervention. Your oncologist will integrate these molecular findings with your clinical stage (Rai or Binet), performance status, and comorbidities to craft a personalized treatment strategy.
2. How should I prepare for the blood sample collection, and is home collection available in the UAE?
No fasting or special preparation is required; simply provide a 4 mL whole blood sample collected in a lavender-top EDTA tube by our DHA-licensed phlebotomist at your convenience. Our VIP Mobile Phlebotomy service operates daily from 8 AM to 11 PM across all seven emirates, with ISO-certified cold-chain transport ensuring specimen integrity from your doorstep to our accredited laboratory. You must complete the Genomics Clinical Information Requisition Form (Form 20) with your ordering physician's details prior to collection. Patients on anticoagulant therapy should inform the phlebotomist before venipuncture. For minors, Federal Decree-Law No. 4 of 2016 on Medical Liability mandates documented parental or legal guardian consent alongside the requisition form.
3. How quickly will I receive my CLL panel results, and who interprets them for me?
Results are delivered within 6 working days when samples arrive by Monday 11 AM, with telephonic post-test clinical guidance included at no additional charge for all patients. Your comprehensive report will detail each genetic marker analyzed — including mutation type, zygosity, and clinical significance tiered according to AMP/ACMG guidelines — and is designed for direct interpretation by your treating oncologist or hematologist. While our clinical counselors provide telephonic result overview and can clarify technical terminology, definitive clinical interpretation and any subsequent treatment modifications must be performed by your licensed specialist physician. Reports are transmitted via encrypted digital channels compliant with UAE PDPL data privacy standards.
UAE Regulatory & Data Privacy Adherence
Legal Mandates:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — Data Privacy
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields
- Federal Decree-Law No. 4 of 2016 on Medical Liability — Patient Consent & Safety
Quality Accreditations:
- ISO 9001:2015 — Cert: INT/EGQ/2509DA/3139
- DHA Facility License: 1143
- Laboratory Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE
- LOINC: 69548-8 — Leukemia-associated genetic variants panel
Clinical & Logistical Metadata
| Test Name | Chronic Lymphocytic Leukemia (CLL) Mutations Detection Comprehensive Panel |
| Price (AED) | 1,500 |
| Turnaround Time | 6 Days (Sample arrival Mon 11 AM → Report by Saturday) |
| Sample Type / Matrix | Whole Blood (4 mL EDTA Lavender Top) – VIP Mobile Phlebotomy & Cold-Chain Home Collection |
| Methodology Used | MLPA + PCR Multiplex |
| ICD-10-CM Code | C91.1 |
| LOINC Code | 69548-8 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians